Spero Therapeutics, Inc.

NasdaqGS:SPRO Stock Report

Market Cap: US$45.3m

Spero Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:SPRO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
05 Feb 25SellUS$53,991Ankit MahadeviaIndividual69,219US$0.78
05 Feb 25SellUS$44,099Timothy KeutzerIndividual56,537US$0.78
05 Feb 25SellUS$121,160Satyavrat ShuklaIndividual155,333US$0.78
05 Feb 25SellUS$16,137Esther RajaveluIndividual20,689US$0.78
08 Nov 24SellUS$53,008Esther RajaveluIndividual40,596US$1.31
27 Aug 24SellUS$3,722Satyavrat ShuklaIndividual2,757US$1.35
27 Aug 24SellUS$2,988Timothy KeutzerIndividual2,213US$1.35
27 Aug 24SellUS$7,981Ankit MahadeviaIndividual5,912US$1.35
05 Aug 24SellUS$42,646Satyavrat ShuklaIndividual32,441US$1.32

Insider Trading Volume

Insider Buying: SPRO insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of SPRO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders973,5991.79%
Public Companies2,362,3484.33%
Hedge Funds3,839,8867.04%
VC/PE Firms9,190,60616.9%
Institutions9,484,94117.4%
General Public28,666,78552.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 46.27% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.9%
SR One Capital Management, LP
9,190,606US$7.6m0%1.93%
7.04%
Anson Group
3,839,886US$3.2m2.38%0.38%
4.33%
Pfizer Inc.
2,362,348US$2.0m0%no data
3.23%
The Vanguard Group, Inc.
1,763,620US$1.5m0%no data
2.03%
Renaissance Technologies LLC
1,105,591US$918.7k13.4%no data
1.91%
Acadian Asset Management LLC
1,039,922US$864.2k-2.98%no data
1.63%
GV Management Company, LLC
889,979US$739.6k0%0.05%
1.6%
Murchinson Ltd.
873,910US$726.2k0%0.33%
1.47%
ADAR1 Capital Management, LLC
801,277US$665.9k7.78%0.14%
0.89%
BlackRock, Inc.
485,352US$403.3k0.11%no data
0.88%
Geode Capital Management, LLC
481,128US$399.8k-0.01%no data
0.64%
Ankit Mahadevia
350,812US$291.5k50.2%no data
0.57%
Monimus Capital Management, LP
310,908US$258.4k0%0.22%
0.56%
Atlas Venture L.P.
305,255US$253.7k-24.2%0.04%
0.34%
Mackenzie Financial Corporation
187,559US$155.9k488%no data
0.34%
Bridgeway Capital Management, LLC
184,800US$153.6k0%no data
0.32%
Citadel Advisors LLC
172,872US$143.7k112%no data
0.27%
State Street Global Advisors, Inc.
148,911US$123.7k14.1%no data
0.27%
Timothy Keutzer
147,003US$122.2k117%no data
0.23%
Satyavrat Shukla
127,852US$106.2k243%no data
0.23%
Dafna Capital Management, LLC
125,000US$103.9k0%0.03%
0.22%
Kamal Hamed
121,418US$100.9k0%no data
0.16%
Northern Trust Global Investments
86,447US$71.8k-22.5%no data
0.11%
JPMorgan Chase & Co, Brokerage and Securities Investments
61,624US$51.2k26,000%no data
0.11%
Tamara Joseph
61,378US$51.0k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 20:53
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Spero Therapeutics, Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
Jason Matthew GerberryBofA Global Research
Joshua SchimmerEvercore ISI